Texas Yale Capital Corp. Acquires New Position in Humana Inc. (NYSE:HUM)

Key Points

• Texas Yale Capital Corp. has acquired a new position in Humana Inc., purchasing 1,350 shares valued at approximately $357,000 in the first quarter.
• Humana reported earnings of $11.58 per share, significantly exceeding analysts' expectations of $10.07, with revenues also beating forecasts at $32.11 billion.
• Institutional investors and hedge funds own approximately 92.38% of Humana's stock, indicating strong interest in the company from these entities.

Texas Yale Capital Corp. acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,350 shares of the insurance provider's stock, valued at approximately $357,000.

A number of other institutional investors have also recently made changes to their positions in HUM. Riverview Trust Co acquired a new position in shares of Humana in the first quarter valued at approximately $34,000. Garde Capital Inc. purchased a new position in Humana in the first quarter worth approximately $36,000. Transce3nd LLC purchased a new position in Humana in the fourth quarter worth approximately $38,000. Whipplewood Advisors LLC lifted its stake in Humana by 639.1% in the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after acquiring an additional 147 shares during the last quarter. Finally, Colonial Trust Advisors lifted its stake in Humana by 4,500.0% in the fourth quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock worth $47,000 after acquiring an additional 180 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Up 3.9%

HUM stock opened at $238.22 on Monday. The company has a fifty day moving average price of $234.56 and a 200 day moving average price of $256.11. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $406.09. The company has a market cap of $28.75 billion, a price-to-earnings ratio of 16.85, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company posted $7.23 EPS. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target for the company. Robert W. Baird decreased their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday. Wells Fargo & Company set a $348.00 price target on shares of Humana in a research note on Friday, July 18th. Mizuho lifted their price target on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Finally, Barclays set a $268.00 price target on shares of Humana and gave the stock an "equal weight" rating in a research note on Thursday, June 12th. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $282.43.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.